214 related articles for article (PubMed ID: 36108903)
1. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
Horino T; Inotani S; Nakajima K; Ohnishi H; Komori M; Terada Y
Joint Bone Spine; 2022 Nov; 89(6):105456. PubMed ID: 36108903
[No Abstract] [Full Text] [Related]
2. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
3. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
4. Prognostic analysis of MDA5-associated clinically amyopathic dermatomyositis with interstitial lung disease.
Wang W; Sun X; Xu Y; Tan W; Liu Y; Zhou J
Immun Inflamm Dis; 2024 Jun; 12(6):e1332. PubMed ID: 38934403
[TBL] [Abstract][Full Text] [Related]
5. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
[TBL] [Abstract][Full Text] [Related]
6. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
Mehta AA; Paul T; Cb M; Haridas N
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33910791
[TBL] [Abstract][Full Text] [Related]
7. [Clinically amyopathic dermatomyositis : a rare entity associated with acute and severe interstitial lung disease].
Debrus C; Calmes D; Von Frenckell C; Duysinx B; Cataldo D; Corhay JL; Louis R; Guiot J
Rev Med Liege; 2023 Jul; 78(7-8):441-447. PubMed ID: 37560958
[TBL] [Abstract][Full Text] [Related]
8. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
9. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
McPherson M; Economidou S; Liampas A; Zis P; Parperis K
Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
[TBL] [Abstract][Full Text] [Related]
12. [Risk Factors of Rapidly Progressive Interstitial Lung Disease in Patients With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis].
Han YY; Jiang T; Zhang ZH; Li W; Jiang YD; Lu CC; Fei Y; Chen B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):422-425. PubMed ID: 36949709
[TBL] [Abstract][Full Text] [Related]
13. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases.
Horai Y; Isomoto E; Koga T; Okada A; Kawashiri SY; Tamai M; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Kuwana M; Kawakami A
Mod Rheumatol; 2013 Jan; 23(1):190-4. PubMed ID: 22460910
[TBL] [Abstract][Full Text] [Related]
14. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease.
Guo L; Zhang X; Pu W; Zhao J; Wang K; Zhang D; Hong S; Ma Y; Wang X; Ye S; Guo Q; Wang J
Rheumatology (Oxford); 2023 Jun; 62(6):2320-2324. PubMed ID: 36637178
[TBL] [Abstract][Full Text] [Related]
15. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
16. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
Nishioka A; Tsunoda S; Abe T; Yoshikawa T; Takata M; Kitano M; Matsui K; Nakashima R; Hosono Y; Ohmura K; Mimori T; Sano H
Mod Rheumatol; 2019 Sep; 29(5):814-820. PubMed ID: 30449228
[No Abstract] [Full Text] [Related]
17. Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.
Hata K; Kotani T; Matsuda S; Fujiki Y; Suzuka T; Kiboshi T; Wada Y; Shiba H; Shoda T; Kagitani M; Takeuchi T
Int J Rheum Dis; 2024 Jan; 27(1):e14999. PubMed ID: 38063858
[TBL] [Abstract][Full Text] [Related]
18. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
[TBL] [Abstract][Full Text] [Related]
19. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
Nandy A; Gaïni S; Sore P
Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
[No Abstract] [Full Text] [Related]
20. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis.
Teruya A; Kawamura K; Ichikado K; Sato S; Yasuda Y; Yoshioka M
Chest; 2013 Dec; 144(6):1934-1936. PubMed ID: 24297126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
